{"id":4280,"date":"2019-02-21T17:13:19","date_gmt":"2019-02-21T11:43:19","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4280"},"modified":"2021-07-24T12:57:13","modified_gmt":"2021-07-24T07:27:13","slug":"pelotontherapeutics","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pelotontherapeutics","title":{"rendered":"Peloton raises $150M; BiomX raises $32M; Abbott and Novo collaborate; Blaze Bioscience nets $5M"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a07b02104e3c\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a07b02104e3c\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pelotontherapeutics\/#Peloton_Therapeutics_raises_USD_150_Million_for_treating_Advance_Kidney_Cancer\" >Peloton Therapeutics raises USD 150 Million for treating Advance Kidney Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pelotontherapeutics\/#BiomX_raises_USD_32_Million_to_eliminate_bacteria\" >BiomX raises USD 32 Million to eliminate bacteria<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pelotontherapeutics\/#Abbott_and_Novo_Nordisk_collaborate_to_assist_Diabetic_patients\" >Abbott and Novo\nNordisk collaborate to assist Diabetic patients<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pelotontherapeutics\/#Blaze_Bioscience_nets_USD_5_Million_to_detect_tumor_cells\" >Blaze Bioscience nets USD 5 Million to detect tumor cells<\/a><\/li><\/ul><\/nav><\/div>\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Peloton_Therapeutics_raises_USD_150_Million_for_treating_Advance_Kidney_Cancer\"><\/span><strong>Peloton Therapeutics raises USD 150 Million for treating Advance Kidney Cancer<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>Peloton Therapeutics<\/strong> has been in the process of developing small molecule drugs to treat&nbsp;<strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/small-cell-lung-cancer-market\">Cancer<\/a><\/strong>, has raised&nbsp;<strong>USD 150 million<\/strong>. Peloton\u2019s lead therapeutic candidate,&nbsp;<strong>PT2977<\/strong>, focuses on targeting&nbsp;<strong>hypoxia-inducible factor-2a, or HIF-2a<\/strong>, in&nbsp;<a href=\"https:\/\/www.delveinsight.com\/report-store\/renal-cell-carcinoma-market\"><strong>Renal cell carcinoma.<\/strong>&nbsp;<\/a>The drug has probable chances for treatment of&nbsp;<strong>Von Hippel-Lindau disease<\/strong>, a<strong>&nbsp;genetic cancer syndrome<\/strong>&nbsp;which at present has no approved drugs.  <\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"BiomX_raises_USD_32_Million_to_eliminate_bacteria\"><\/span><strong>BiomX raises USD 32 Million to eliminate bacteria<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>BiomX<\/strong> has netted&nbsp;<strong>USD 32<\/strong>&nbsp;<strong>million<\/strong>&nbsp;to eliminate the existence of <a href=\"https:\/\/www.delveinsight.com\/report-store\/skin-and-skin-structure-infections-sssi-caused-by-bacteria-market\"><strong>bacteria<\/strong> <\/a>causing&nbsp;<strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/acne-vulgaris-av-market\">Acne&nbsp;<\/a><\/strong>and&nbsp;<strong>Inflammatory <a href=\"https:\/\/www.delveinsight.com\/report-store\/irritable-bowel-syndrome-ibs-market\">bowel <\/a>disease<\/strong>. The treatment as of now is in pre-clinical trials. The&nbsp;<strong>bacteriophage,&nbsp;in&nbsp;development,<\/strong> stays active against&nbsp;<strong>antibiotic-resistant strains<\/strong>&nbsp;of&nbsp;<strong>Propionibacterium acnes<\/strong>&nbsp;leaving the others present in the skin. In addition, it has the ability to replicate itself producing up to 100 more from each bacteria it destroys.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Abbott_and_Novo_Nordisk_collaborate_to_assist_Diabetic_patients\"><\/span><strong>Abbott and Novo\nNordisk <\/strong><strong>collaborate <\/strong><strong>to assist Diabetic patients<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>Abbott&nbsp;<\/strong>and&nbsp;<strong>Novo Nordisk<\/strong>&nbsp;entered into a non-exclusive agreement to incorporate insulin dose data from Novo Nordisk prefilled and durable pens into the&nbsp;<strong>digital health tools&nbsp;<\/strong>compatible with the&nbsp;<strong>FreeStyle Libre system<\/strong>. The alliance is keen on making&nbsp;<a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-nephropathy-market\"><strong>Diabetes<\/strong>&nbsp;<\/a>management simpler. It linked key technologies such as&nbsp;<strong>continuous <a href=\"https:\/\/www.delveinsight.com\/report-store\/low-affinity-sodium-glucose-cotransporter-sglt2-inhibitor-pipeline-insight\">glucose <\/a>monitoring (CGM)<\/strong>&nbsp;and connected&nbsp;<a href=\"https:\/\/www.delveinsight.com\/report-store\/insulin-resistance-market\"><strong>insulin<\/strong>&nbsp;<\/a>pens. So, this will help the affected people to study their&nbsp;<strong>glucose<\/strong>&nbsp;and insulin data together. It will help in making more informed treatment decisions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Blaze_Bioscience_nets_USD_5_Million_to_detect_tumor_cells\"><\/span><strong>Blaze Bioscience nets USD 5 Million to detect tumor cells<\/strong> <br><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>Blaze Bioscience<\/strong>, Seattle-based biotech has raised&nbsp;<strong>USD 5 Million<\/strong>&nbsp;to develop a&nbsp;<strong>\u2018TUMOR PAINT\u2019<\/strong>&nbsp;that can differentiate&nbsp;<strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/pancreatic-endocrine-tumor-market\">tumor <\/a>cells<\/strong>&nbsp;from the normal ones<strong>. BLZ-100<\/strong>-Blaze&#8217;s main product is a fluorescent imaging agent. It is injected intravenously in<strong>&nbsp;<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/medullary-thyroid-cancer-market\"><strong>Cancer<\/strong>&nbsp;<\/a>patients before the operation begins. Therefore, it helps surgeons to easily identify them. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Peloton Therapeutics raises USD 150 Million for treating Advance Kidney Cancer Peloton Therapeutics has been in the process of developing small molecule drugs to treat&nbsp;Cancer, has raised&nbsp;USD 150 million. Peloton\u2019s lead therapeutic candidate,&nbsp;PT2977, focuses on targeting&nbsp;hypoxia-inducible factor-2a, or HIF-2a, in&nbsp;Renal cell carcinoma.&nbsp;The drug has probable chances for treatment of&nbsp;Von Hippel-Lindau disease, a&nbsp;genetic cancer syndrome&nbsp;which at [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4086,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2405,2591,2593,2590,2592,2589,2600,2602,2594,137,812,2598,2599,2587,2597,2586,2595,2574,877,2584,2596,2585,854,1705,2601,2588],"industry":[17225],"therapeutic_areas":[17237,17240,17238,17231],"class_list":["post-4280","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-abbott","tag-acne","tag-antibiotic-resistant","tag-bacteria","tag-bacteriophage","tag-biomx","tag-blaze-bioscience","tag-blz-100","tag-bowel","tag-cancer","tag-diabetes","tag-digital-health-tools","tag-freestyle-libre-system","tag-genetic-cancer-syndrome","tag-glucose","tag-hypoxia-inducible-factor-2a","tag-inflammatory-bowel-disease","tag-insulin","tag-novo-nordisk","tag-peloton-therapeutics","tag-propionibacterium-acnes","tag-pt2977","tag-renal-cell-carcinoma","tag-tumor","tag-tumor-paint","tag-von-hippel-lindau-disease","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-genetic-disorders","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Peloton raises $150M; BiomX raises $32M; Abbott and Novo collaborate<\/title>\n<meta name=\"description\" content=\"Peloton Therapeutics has been in the process of developing small molecule drugs to treat Cancer has raised USD 150 million............\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pelotontherapeutics\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Peloton raises $150M; BiomX raises $32M; Abbott and Novo collaborate\" \/>\n<meta property=\"og:description\" content=\"Peloton Therapeutics has been in the process of developing small molecule drugs to treat Cancer has raised USD 150 million............\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pelotontherapeutics\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-02-21T11:43:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/02\/09021654\/Pharma-Money.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"804\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Peloton raises $150M; BiomX raises $32M; Abbott and Novo collaborate","description":"Peloton Therapeutics has been in the process of developing small molecule drugs to treat Cancer has raised USD 150 million............","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pelotontherapeutics","og_locale":"en_US","og_type":"article","og_title":"Peloton raises $150M; BiomX raises $32M; Abbott and Novo collaborate","og_description":"Peloton Therapeutics has been in the process of developing small molecule drugs to treat Cancer has raised USD 150 million............","og_url":"https:\/\/www.delveinsight.com\/blog\/pelotontherapeutics","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-02-21T11:43:19+00:00","article_modified_time":"2021-07-24T07:27:13+00:00","og_image":[{"width":1200,"height":804,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/02\/09021654\/Pharma-Money.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pelotontherapeutics","url":"https:\/\/www.delveinsight.com\/blog\/pelotontherapeutics","name":"Peloton raises $150M; BiomX raises $32M; Abbott and Novo collaborate","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pelotontherapeutics#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pelotontherapeutics#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/02\/09021654\/Pharma-Money.jpg","datePublished":"2019-02-21T11:43:19+00:00","dateModified":"2021-07-24T07:27:13+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Peloton Therapeutics has been in the process of developing small molecule drugs to treat Cancer has raised USD 150 million............","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pelotontherapeutics"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pelotontherapeutics#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/02\/09021654\/Pharma-Money.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/02\/09021654\/Pharma-Money.jpg","width":1200,"height":804,"caption":"Peloton Therapeutics"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/02\/09021654\/Pharma-Money-300x201.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Abbott<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Acne<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">antibiotic-resistant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">bacteria<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">bacteriophage<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BiomX<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Blaze Bioscience<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BLZ-100<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">bowel<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Diabetes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">digital health tools<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FreeStyle Libre system<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">genetic cancer syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">glucose<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">hypoxia-inducible factor-2a<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Inflammatory bowel disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">insulin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novo Nordisk<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Peloton therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Propionibacterium acnes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">PT2977<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Renal Cell Carcinoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tumor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">TUMOR PAINT<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Von Hippel-Lindau disease<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Abbott<\/span>","<span class=\"advgb-post-tax-term\">Acne<\/span>","<span class=\"advgb-post-tax-term\">antibiotic-resistant<\/span>","<span class=\"advgb-post-tax-term\">bacteria<\/span>","<span class=\"advgb-post-tax-term\">bacteriophage<\/span>","<span class=\"advgb-post-tax-term\">BiomX<\/span>","<span class=\"advgb-post-tax-term\">Blaze Bioscience<\/span>","<span class=\"advgb-post-tax-term\">BLZ-100<\/span>","<span class=\"advgb-post-tax-term\">bowel<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Diabetes<\/span>","<span class=\"advgb-post-tax-term\">digital health tools<\/span>","<span class=\"advgb-post-tax-term\">FreeStyle Libre system<\/span>","<span class=\"advgb-post-tax-term\">genetic cancer syndrome<\/span>","<span class=\"advgb-post-tax-term\">glucose<\/span>","<span class=\"advgb-post-tax-term\">hypoxia-inducible factor-2a<\/span>","<span class=\"advgb-post-tax-term\">Inflammatory bowel disease<\/span>","<span class=\"advgb-post-tax-term\">insulin<\/span>","<span class=\"advgb-post-tax-term\">Novo Nordisk<\/span>","<span class=\"advgb-post-tax-term\">Peloton therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Propionibacterium acnes<\/span>","<span class=\"advgb-post-tax-term\">PT2977<\/span>","<span class=\"advgb-post-tax-term\">Renal Cell Carcinoma<\/span>","<span class=\"advgb-post-tax-term\">Tumor<\/span>","<span class=\"advgb-post-tax-term\">TUMOR PAINT<\/span>","<span class=\"advgb-post-tax-term\">Von Hippel-Lindau disease<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Feb 21, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Feb 21, 2019 5:13 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4280"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4280\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4086"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4280"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4280"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}